Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCR	IBER	PATIENT:				
Name:		Name:				
Nard:		NHI:				
<i>l</i> lening	ococcal B multicomponent vaccine					
Re-asse	ON – Primary immunisation for children up to 12 months of ag ssment required after 3 doses isites (tick boxes where appropriate)	je				
or	Or Three doses for children up to 12 months of age (inclusive) for primary immunisation O Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025					
	ON – Person is one year of age or over isites (tick boxes where appropriate)					
or or or	asplenia, HIV, complement deficiency (acquired or inherited Up to two doses for close contacts of meningococcal cases Up to two doses for person who has previously had meningo	of any group ococcal disease of any group				
Re-asse	ON – Person is aged between 13 and 25 years (inclusive) ssment required after 2 doses visites (tick boxes where appropriate)					
an						
	'Immunosuppression due to corticosteroid or other immunosuppre than 28 days.	essive therapy must be for a period of				

I confirm that the above details are correct:

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	